| Serial MRI and CSF biomarkers in normal aging, MCI, and AD. | |
| | |
MedLine Citation:
|
PMID: 20625167 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To compare the annual change in MRI and CSF biomarkers in cognitively normal (CN), amnestic mild cognitive impairment (aMCI), and Alzheimer disease (AD). Comparisons were based on intergroup discrimination, correlation with concurrent cognitive/functional changes, relationships to APOE genotype, and sample sizes for clinical trials. METHODS: We used data from the Alzheimer's Disease Neuroimaging Initiative study consisting of CN, aMCI, and AD cohorts with both baseline and 12-month follow-up CSF and MRI. The annual change in CSF (total-tau [t-tau], Abeta(1-42)) and MRI (change in ventricular volume) was obtained in 312 subjects (92 CN, 149 aMCI, 71 AD). RESULTS: There was no significant average annual change in either CSF biomarker in any clinical group except t-tau in CN; moreover, the annual change did not differ by clinical group in pairwise comparisons. In contrast, annual increase in ventricular volume increased in the following order, AD > aMCI > CN, and differences were significant between all clinical groups in pairwise comparisons. Ventricular volume increase correlated with concurrent worsening on cognitive/functional indices in aMCI and AD whereas evidence of a similar correlation with change in CSF measures was unclear. The annual changes in MRI differed by APOE epsilon4 status overall and among aMCI while annual changes in CSF biomarkers did not. Estimated sample sizes for clinical trials are notably less for MRI than the CSF or clinical measures. CONCLUSIONS: Unlike the CSF biomarkers evaluated, changes in serial structural MRI are correlated with concurrent change on general cognitive and functional indices in impaired subjects, track with clinical disease stage, and are influenced by APOE genotype. |
| | |
Authors:
|
P Vemuri; H J Wiste; S D Weigand; D S Knopman; J Q Trojanowski; L M Shaw; M A Bernstein; P S Aisen; M Weiner; R C Petersen; C R Jack; |
Related Documents
:
|
1835787 - Neuropsychological, neurological, and mri correlates of dementia in advanced huntington... 18191587 - In vivo spect imaging of vesicular acetylcholine transporter using [(123)i]-ibvm in ear... 8416587 - Functional importance of ventricular enlargement and cortical atrophy in healthy subjec... 3315157 - Progressive supranuclear palsy. 11827877 - High-resolution line scan diffusion tensor mr imaging of white matter fiber tract anatomy. 17453217 - Quantitative evaluation of muscle perfusion with ceus and with mr. |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S. |
Journal Detail:
|
Title: Neurology Volume: 75 ISSN: 1526-632X ISO Abbreviation: Neurology Publication Date: 2010 Jul |
Date Detail:
|
Created Date: 2010-07-13 Completed Date: 2010-07-30 Revised Date: 2011-08-01 |
Medline Journal Info:
|
Nlm Unique ID: 0401060 Medline TA: Neurology Country: United States |
Other Details:
|
Languages: eng Pagination: 143-51 Citation Subset: AIM; IM |
Affiliation:
|
Aging and Dementia Imaging Research Laboratory, Department of Radiology, Mayo Clinic and Foundation, Rochester, MN 55905, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Age Factors Aged Aged, 80 and over Aging / cerebrospinal fluid*, genetics, pathology Alzheimer Disease / cerebrospinal fluid*, genetics, pathology Amyloid beta-Peptides / cerebrospinal fluid* Apolipoproteins E / genetics Biological Markers / cerebrospinal fluid Brain / pathology* Cognition Disorders / cerebrospinal fluid*, genetics, pathology Female Genetic Predisposition to Disease Humans Magnetic Resonance Imaging Male Neuropsychological Tests Peptide Fragments / cerebrospinal fluid* Reference Values Regression Analysis Severity of Illness Index tau Proteins / cerebrospinal fluid* |
| Grant Support | |
ID/Acronym/Agency:
|
1 U01 AG 024904-05/AG/NIA NIH HHS; 1P01 AG-19724-07/AG/NIA NIH HHS; AG023195/AG/NIA NIH HHS; AG024904/AG/NIA NIH HHS; AG11378/AG/NIA NIH HHS; AG24904-01/AG/NIA NIH HHS; C06 RR018898/RR/NCRR NIH HHS; P01 AG 09215-20/AG/NIA NIH HHS; P01 AG 17586-10/AG/NIA NIH HHS; P01AG012435/AG/NIA NIH HHS; P01AG19724/AG/NIA NIH HHS; P30 AG 10124-18/AG/NIA NIH HHS; P30AG036468/AG/NIA NIH HHS; P41 RR023953/RR/NCRR NIH HHS; P50 AG 16574/AG/NIA NIH HHS; P50 AG16574/AG/NIA NIH HHS; P50 NS053488-02/NS/NINDS NIH HHS; P50-AG16574/AG/NIA NIH HHS; P50AG23501/AG/NIA NIH HHS; R01 AG011378-19/AG/NIA NIH HHS; R01 AG10897/AG/NIA NIH HHS; R01 HL70825/HL/NHLBI NIH HHS; R01 NS031966/NS/NINDS NIH HHS; R01-AG030048/AG/NIA NIH HHS; R01-AG11378/AG/NIA NIH HHS; R01-AG16381/AG/NIA NIH HHS; R01AG11378/AG/NIA NIH HHS; R24 RR021992/RR/NCRR NIH HHS; RC1AG035427/AG/NIA NIH HHS; RC2NS069368/NS/NINDS NIH HHS; U01 AG 024904/AG/NIA NIH HHS; U01 AG 06786/AG/NIA NIH HHS; U01 AG024904-01/AG/NIA NIH HHS; U01 AG06786/AG/NIA NIH HHS; U01-AG024904/AG/NIA NIH HHS; U01-AG10483/AG/NIA NIH HHS; U01AG024904/AG/NIA NIH HHS; UO1AG029213-01/AG/NIA NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Amyloid beta-Peptides; 0/Apolipoproteins E; 0/Biological Markers; 0/Peptide Fragments; 0/amyloid beta-protein (1-42); 0/tau Proteins |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Head circumference, atrophy, and cognition: implications for brain reserve in Alzheimer disease.
Next Document: Use of anticholinergics and the risk of cognitive impairment in an African American population.